Thursday, February 26, 2015

Biotech Investing: Merrimack (MACK) stops trial of MM-111

Merrimack ceased Phase 2 trials of its investigatory drug MM-111 after the DSMB review showed that Progression Free Survival was worse in the compounds arm versus the control arm.  The company has a number of compounds in its pipeline so it's not a huge hit but still a negative.

The company's lead compound, MM-398, is being submitted to the FDA to treat Pancreatic Cancer.  I would expect the PDUFA date sometime in the 4th quarter of this year which is a major trade catalyst.

Also, they hinted in today's 4th quarter results call that they are looking to secure a partner prior to initiating a pivotal trial in breast cancer with another advanced compound, MM-121.  I wouldn't be surprised if they come through with a partner based on the impressive Phase 2 results in the subgroup that they plan to target in the pivotal trial.

Good luck fellow Biotech Investors!

No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com